vs

Side-by-side financial comparison of Edwards Lifesciences (EW) and JBT Marel Corp (JBTM). Click either name above to swap in a different company.

Edwards Lifesciences is the larger business by last-quarter revenue ($1.6B vs $1.0B, roughly 1.6× JBT Marel Corp). Edwards Lifesciences runs the higher net margin — 23.1% vs 5.3%, a 17.8% gap on every dollar of revenue. On growth, JBT Marel Corp posted the faster year-over-year revenue change (115.6% vs 16.7%). Over the past eight quarters, JBT Marel Corp's revenue compounded faster (60.3% CAGR vs 9.7%).

Edwards Lifesciences Corporation is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring. It developed the Sapien transcatheter aortic heart valve made of cow tissue within a balloon-expandable, cobalt-chromium frame, deployed via catheter.

JBT Marel Corporation, formerly known as JBT Corporation, or John Bean Technologies Corporation, is a food processing machinery and automated vehicle company. The company was incorporated in 2008 when FMC Technologies divested its non-energy businesses. The company is based in Chicago, Illinois and traces its history back to a company founded in 1884 by John Bean, an orchardist in Los Gatos, California.

EW vs JBTM — Head-to-Head

Bigger by revenue
EW
EW
1.6× larger
EW
$1.6B
$1.0B
JBTM
Growing faster (revenue YoY)
JBTM
JBTM
+98.9% gap
JBTM
115.6%
16.7%
EW
Higher net margin
EW
EW
17.8% more per $
EW
23.1%
5.3%
JBTM
Faster 2-yr revenue CAGR
JBTM
JBTM
Annualised
JBTM
60.3%
9.7%
EW

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
EW
EW
JBTM
JBTM
Revenue
$1.6B
$1.0B
Net Profit
$380.7M
$53.1M
Gross Margin
78.0%
34.5%
Operating Margin
1.8%
7.2%
Net Margin
23.1%
5.3%
Revenue YoY
16.7%
115.6%
Net Profit YoY
6.8%
858.6%
EPS (diluted)
$0.66
$1.04

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
EW
EW
JBTM
JBTM
Q1 26
$1.6B
Q4 25
$1.6B
$1.0B
Q3 25
$1.6B
$1.0B
Q2 25
$1.5B
$934.8M
Q1 25
$1.4B
$854.1M
Q4 24
$1.4B
$467.6M
Q3 24
$1.4B
$453.8M
Q2 24
$1.4B
$402.3M
Net Profit
EW
EW
JBTM
JBTM
Q1 26
$380.7M
Q4 25
$91.2M
$53.1M
Q3 25
$291.1M
$66.0M
Q2 25
$333.2M
$3.4M
Q1 25
$358.0M
$-173.0M
Q4 24
$385.6M
$-7.0M
Q3 24
$3.1B
$38.9M
Q2 24
$366.3M
$30.7M
Gross Margin
EW
EW
JBTM
JBTM
Q1 26
78.0%
Q4 25
78.1%
34.5%
Q3 25
77.8%
35.9%
Q2 25
77.5%
35.8%
Q1 25
78.7%
34.2%
Q4 24
78.9%
38.4%
Q3 24
80.6%
36.1%
Q2 24
79.9%
35.6%
Operating Margin
EW
EW
JBTM
JBTM
Q1 26
1.8%
Q4 25
9.6%
7.2%
Q3 25
19.8%
10.2%
Q2 25
26.8%
5.2%
Q1 25
27.9%
-3.9%
Q4 24
22.6%
3.4%
Q3 24
25.9%
10.3%
Q2 24
26.8%
6.7%
Net Margin
EW
EW
JBTM
JBTM
Q1 26
23.1%
Q4 25
5.8%
5.3%
Q3 25
18.7%
6.6%
Q2 25
21.7%
0.4%
Q1 25
25.3%
-20.3%
Q4 24
27.8%
-1.5%
Q3 24
226.7%
8.6%
Q2 24
26.7%
7.6%
EPS (diluted)
EW
EW
JBTM
JBTM
Q1 26
$0.66
Q4 25
$0.16
$1.04
Q3 25
$0.50
$1.26
Q2 25
$0.56
$0.07
Q1 25
$0.61
$-3.35
Q4 24
$0.65
$-0.22
Q3 24
$5.13
$1.21
Q2 24
$0.61
$0.95

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
EW
EW
JBTM
JBTM
Cash + ST InvestmentsLiquidity on hand
$167.9M
Total DebtLower is stronger
$1.5B
Stockholders' EquityBook value
$4.5B
Total Assets
$8.2B
Debt / EquityLower = less leverage
0.33×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
EW
EW
JBTM
JBTM
Q1 26
Q4 25
$4.2B
$167.9M
Q3 25
$3.8B
Q2 25
$4.1B
Q1 25
$3.9B
Q4 24
$4.0B
$1.2B
Q3 24
$4.4B
Q2 24
$2.0B
Total Debt
EW
EW
JBTM
JBTM
Q1 26
Q4 25
$1.5B
Q3 25
$1.5B
Q2 25
$1.5B
Q1 25
$2.0B
Q4 24
$1.3B
Q3 24
$648.3M
Q2 24
$647.7M
Stockholders' Equity
EW
EW
JBTM
JBTM
Q1 26
Q4 25
$10.3B
$4.5B
Q3 25
$10.2B
$4.4B
Q2 25
$10.5B
$4.4B
Q1 25
$10.1B
$4.1B
Q4 24
$10.0B
$1.5B
Q3 24
$9.5B
$1.6B
Q2 24
$7.4B
$1.5B
Total Assets
EW
EW
JBTM
JBTM
Q1 26
Q4 25
$13.7B
$8.2B
Q3 25
$13.3B
$8.2B
Q2 25
$13.5B
$8.3B
Q1 25
$13.0B
$8.0B
Q4 24
$13.1B
$3.4B
Q3 24
$13.0B
$2.8B
Q2 24
$10.1B
$2.7B
Debt / Equity
EW
EW
JBTM
JBTM
Q1 26
Q4 25
0.33×
Q3 25
0.34×
Q2 25
0.35×
Q1 25
0.48×
Q4 24
0.81×
Q3 24
0.41×
Q2 24
0.43×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
EW
EW
JBTM
JBTM
Operating Cash FlowLast quarter
$117.4M
Free Cash FlowOCF − Capex
$83.5M
FCF MarginFCF / Revenue
8.3%
Capex IntensityCapex / Revenue
3.4%
Cash ConversionOCF / Net Profit
2.21×
TTM Free Cash FlowTrailing 4 quarters
$238.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
EW
EW
JBTM
JBTM
Q1 26
Q4 25
$450.9M
$117.4M
Q3 25
$573.7M
$87.7M
Q2 25
$290.2M
$102.2M
Q1 25
$280.4M
$34.4M
Q4 24
$-127.5M
$128.7M
Q3 24
$351.8M
$71.9M
Q2 24
$371.5M
$21.6M
Free Cash Flow
EW
EW
JBTM
JBTM
Q1 26
Q4 25
$353.5M
$83.5M
Q3 25
$516.2M
$56.5M
Q2 25
$240.9M
$83.7M
Q1 25
$224.4M
$14.4M
Q4 24
$-177.3M
$118.7M
Q3 24
$299.9M
$65.0M
Q2 24
$286.1M
$11.1M
FCF Margin
EW
EW
JBTM
JBTM
Q1 26
Q4 25
22.5%
8.3%
Q3 25
33.2%
5.6%
Q2 25
15.7%
9.0%
Q1 25
15.9%
1.7%
Q4 24
-12.8%
25.4%
Q3 24
22.1%
14.3%
Q2 24
20.9%
2.8%
Capex Intensity
EW
EW
JBTM
JBTM
Q1 26
Q4 25
6.2%
3.4%
Q3 25
3.7%
3.1%
Q2 25
3.2%
2.0%
Q1 25
4.0%
2.3%
Q4 24
3.6%
2.1%
Q3 24
3.8%
1.5%
Q2 24
6.2%
2.6%
Cash Conversion
EW
EW
JBTM
JBTM
Q1 26
Q4 25
4.94×
2.21×
Q3 25
1.97×
1.33×
Q2 25
0.87×
30.06×
Q1 25
0.78×
Q4 24
-0.33×
Q3 24
0.11×
1.85×
Q2 24
1.01×
0.70×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons